Reuters logo
BRIEF-Pfizer says Besponsa approved in the EU for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia
June 30, 2017 / 11:56 AM / in 4 months

BRIEF-Pfizer says Besponsa approved in the EU for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia

June 30 (Reuters) - Pfizer Inc

* Besponsa® approved in the EU for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia

* Pfizer Inc - Prescription Drug User Fee Act (PDUFA) goal date for a decision by FDA is august 2017. Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below